Printer Friendly

ESN cuts Arseus to "accumulate".

(ADPnews) - Aug 24, 2009 - ESN Analyser lowered its recommendation on Belgian health products wholesaler Arseus NV (EBR:RCUS) to "accumulate" from "buy".

Although the company's first-half results were largely in line with the expectations, the company's capital management continues to raise concerns.

Arseus has currently insufficient financial resources to keep its inventories intact. As a result, the company is threatened to lose its big market share in the domestic wheel chair sector.

Arseus announced Friday a net profit of EUR 9.4 million (USD 13.4m) for the first half of 2009, down 5.1% in annual terms, chiefly due to one-off write-downs.

At 1205 CET on Monday Arseus was up 1.03% to EUR 7.84 in Brussels.

(EUR 1.0 = USD 1.429)

COPYRIGHT 2009 AII Data Processing Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:ADP News Belgium
Date:Aug 24, 2009
Words:125
Previous Article:Belgian Leasinvest H1 2009 net current profit jumps 25% y/y.
Next Article:Belgian Evadix trade suspended on Tuesday.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters